托法替布联合维迪西妥单抗治疗上尿路尿路上皮癌所致间质性肺疾病：一例报告及文献复习 - Suppr

Interstitial lung disease induced by Toripalimab combined with disitamab Vedotin in upper tract urothelial carcinoma: a case report and literature review.

作者信息

Ding Peng, Lin Huanhuan, Zhang Kaichen, Yang Qian, Gao Peiyang

机构信息

Department of Critical Care Medicine, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China.

Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China.

出版信息

BMC Pulm Med. 2025 Jul 24;25(1):351. doi: 10.1186/s12890-025-03838-z.

DOI:10.1186/s12890-025-03838-z

PMID:40707939

Abstract

摘要

相似文献

Interstitial lung disease induced by Toripalimab combined with disitamab Vedotin in upper tract urothelial carcinoma: a case report and literature review.

BMC Pulm Med. 2025 Jul 24;25(1):351. doi: 10.1186/s12890-025-03838-z.

SGNDV-001: disitamab vedotin with pembrolizumab in HER2-expressing locally advanced or metastatic urothelial carcinoma.

Future Oncol. 2025 Jul 29:1-8. doi: 10.1080/14796694.2025.2535280.

Efficacy of Disitamab Vedotin in a heavily pre-treated HER2 positive lung adenocarcinoma patient: case report and literature review.

Heliyon. 2022 Sep 16;8(9):e10581. doi: 10.1016/j.heliyon.2022.e10581. eCollection 2022 Sep.

TNF Signaling Pathway Is the Key Pathway Regulated by Disitamab Vedotin in Bladder Cancer Cells.

Curr Issues Mol Biol. 2025 May 18;47(5):369. doi: 10.3390/cimb47050369.

Case report: Successful treatment of advanced urothelial carcinoma with trophoblastic differentiation using Tislelizumab and Disitamab vedotin.

Heliyon. 2024 Sep 26;10(19):e38518. doi: 10.1016/j.heliyon.2024.e38518. eCollection 2024 Oct 15.

Disitamab vedotin plus toripalimab in patients with locally advanced or metastatic urothelial carcinoma (RC48-C014): a phase Ib/II dose-escalation and dose-expansion study.

Ann Oncol. 2025 Mar;36(3):331-339. doi: 10.1016/j.annonc.2024.12.002. Epub 2024 Dec 9.

Evaluating the efficacy and safety of bladder-sparing regimen with Disitamab Vedotin combined with Toripalimab and pelvic lymph node dissection in muscle-invasive bladder cancer patients: study protocol of a multicenter single-arm phase II trial.

BMC Cancer. 2025 May 13;25(1):868. doi: 10.1186/s12885-025-14234-5.

Toripalimab plus bevacizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma (HEPATORCH): a randomised, open-label, phase 3 trial.

Lancet Gastroenterol Hepatol. 2025 Jul;10(7):658-670. doi: 10.1016/S2468-1253(25)00059-7. Epub 2025 May 20.

Disitamab vedotin (RC48) long-term regimen in a post-nephroureterectomy patient with metastases: a case report.

Front Oncol. 2024 Sep 13;14:1419882. doi: 10.3389/fonc.2024.1419882. eCollection 2024.

Disitamab Vedotin: First Approval.

Drugs. 2021 Nov;81(16):1929-1935. doi: 10.1007/s40265-021-01614-x.

本文引用的文献

European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: Summary of the 2025 Update.

Eur Urol. 2025 Jun;87(6):697-716. doi: 10.1016/j.eururo.2025.02.023. Epub 2025 Mar 20.

Recent advances in the study of immune checkpoint inhibitor-associated pneumonia.

Crit Rev Oncol Hematol. 2025 Feb;206:104591. doi: 10.1016/j.critrevonc.2024.104591. Epub 2024 Dec 10.

Disitamab vedotin plus toripalimab in patients with locally advanced or metastatic urothelial carcinoma (RC48-C014): a phase Ib/II dose-escalation and dose-expansion study.

Ann Oncol. 2025 Mar;36(3):331-339. doi: 10.1016/j.annonc.2024.12.002. Epub 2024 Dec 9.

Safety and efficacy of antibody-drug conjugates plus immunotherapy in solid tumours: A systematic review and meta-analysis.

Cancer Treat Rev. 2024 Dec;131:102847. doi: 10.1016/j.ctrv.2024.102847. Epub 2024 Oct 18.

Cancer therapy-related interstitial lung disease.

Chin Med J (Engl). 2025 Feb 5;138(3):264-277. doi: 10.1097/CM9.0000000000003149. Epub 2024 Oct 11.

Adverse Events of PD-1, PD-L1, CTLA-4, and LAG-3 Immune Checkpoint Inhibitors: An Analysis of the FDA Adverse Events Database.

Antibodies (Basel). 2024 Jul 17;13(3):59. doi: 10.3390/antib13030059.

Risk factors and immunomodulators use in steroid-refractory checkpoint inhibitor pneumonitis.

J Immunother Cancer. 2023 Jun;11(6). doi: 10.1136/jitc-2023-006982.

European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2023 Update.

Eur Urol. 2023 Jul;84(1):49-64. doi: 10.1016/j.eururo.2023.03.013. Epub 2023 Mar 24.

Disitamab vedotin: a novel antibody-drug conjugates for cancer therapy.

Drug Deliv. 2022 Dec;29(1):1335-1344. doi: 10.1080/10717544.2022.2069883.

Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons.

Cell Commun Signal. 2022 Apr 7;20(1):44. doi: 10.1186/s12964-022-00854-y.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Interstitial lung disease induced by Toripalimab combined with disitamab Vedotin in upper tract urothelial carcinoma: a case report and literature review.

作者信息

机构信息

出版信息

相似文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

Interstitial lung disease induced by Toripalimab combined with disitamab Vedotin in upper tract urothelial carcinoma: a case report and literature review.

作者信息

机构信息

出版信息

相似文献

本文引用的文献